Results 231 to 240 of about 9,207,506 (367)

First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim To evaluate the safety, tolerability and pharmacokinetics in healthy participants of orally administered MMV367 (GSK3772701), a novel antimalarial interfering with Plasmodium falciparum acyl coenzyme A synthetase 10/11 function. Methods This first‐in‐human study enrolled 47 healthy male and female participants.
Andrea Kuemmerle, Nand Singh, Denis Gossen, Annick Janin, Raman Sharma, Anthony Cahn, Rachel A. Gibson, Somasekhara R. Menakuru, Erin Lambourne, Tom Dove, Francisco‐Javier Gamo, Laura Sanz, Benoit Bestgen, Stephan Chalon   +13 more
wiley   +1 more source

An unusual cause of hepato-biliary disease in an immunocompromised patient. [PDF]

Access Microbiol, 2019
Johnson A, Gupta S, Meyrick S, Davies AP, Chalmers R.   +4 more
europepmc   +1 more source

Coeliac disease and primary biliary cirrhosis: a case for mutual screening [PDF]

, 1998
Jane Metcalf
openalex   +1 more source

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.
Sarah Alrubia, Brahim Achour, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, Jill Barber   +4 more
wiley   +1 more source

New perspectives on the pathogenesis ofCryptosporidium biliary disease [PDF]

, 1998
Robert L. Owen
openalex   +1 more source

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paltusotine is a novel, nonpeptide, selective somatostatin receptor 2 agonist in development for the treatment of acromegaly and carcinoid syndrome. This study investigated the mass balance, routes of excretion, absolute bioavailability and metabolite profile of orally administered paltusotine.
Rosa Luo, Ajay Madan, Christine T. Ferrara‐Cook, Deepak Dalvie, Lance Goulet, R. Scott Struthers, Alan S. Krasner   +6 more
wiley   +1 more source

Liver and Biliary Disease [PDF]

Gut, 1980
openaire   +2 more sources

Paracetamol and its metabolites in children and adults with spinal muscular atrophy – a population pharmacokinetic model

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of the study was to investigate whether differences in paracetamol pharmacokinetics (PK) between spinal muscular atrophy (SMA) patients and healthy controls (HC) could be attributed to specific clinical covariates. Methods Nonlinear mixed‐effects modelling (NONMEM 7.4) was used to develop a population PK model, explore covariates ...
Qiaolin Zhao, Marie Mostue Naume, Brenda C. M. de Winter, Thomas Krag, Sissel Sundell Haslund‐Krog, Karoline Lolk Revsbech, John Vissing, Helle Holst, Morten Hylander Møller, Tessa Munkeboe Hornsyld, Morten Dunø, Christina Engel Hoei‐Hansen, Alfred Peter Born, Per Bo Jensen, Mette Cathrine Ørngreen   +14 more
wiley   +1 more source

Liver and biliary disease research supported by the National Institutes of Health [PDF]

, 1997
T Kresina
openalex   +1 more source

Flux Sampling Suggests Metabolic Signatures of High Antibody‐Producing CHO Cells

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Chinese hamster ovary (CHO) cells remain the industry standard for producing numerous therapeutic proteins, particularly monoclonal antibodies (mAbs). However, achieving higher recombinant protein titers remains an ongoing challenge and a fundamental understanding of the cellular mechanism driving improved bioprocess performance remains ...
Kate E. Meeson, Joanne Watson, Susan Rosser, Ellie Hawke, Andrew Pitt, Tessa Moses, Leon Pybus, Magnus Rattray, Alan J. Dickson, Jean‐Marc Schwartz   +9 more
wiley   +1 more source